Flubromazolam’s part in clinical trials is proscribed because of its classification being a designer drug. However, its consequences have already been reversed by the benzodiazepine antagonist flumazenil in pharmacokinetic scientific tests, offering insights into its medical implications and crisis management of overdoses.Advertise your boat on